Leflunomide

Key Product Details

Product Description

Inhibitor of dihydroorotate dehydrogenase (IC₅₀ = 2.5 μM). Inhibits de novo pyrimidine synthesis in human T cells in vitro; also inhibits lymphocyte proliferation. Exhibits efficacy in several animal models of autoimmune disease, arthritis and graft rejection. Active metabolite, teriflunomide (A77 1726, Cat. No. 5069), also available.

Product Specifications for Leflunomide

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Leflunomide

The following data is based on the product molecular weight 270.21.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	3.70 mL	18.50 mL	37.01 mL
5 mM	0.74 mL	3.70 mL	7.40 mL
10 mM	0.37 mL	1.85 mL	3.70 mL
50 mM	0.07 mL	0.37 mL	0.74 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 7 publications citing the usage of this product.

• Cherwinski The immunosuppressant leflun. inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J.Pharmacol.Exp.Ther. 1995 PMID: 7473131
• Brazelton and Morris Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacro. (FK506), siro. (rapamycin), mycophen. mofetil and leflun. Curr.Opin.Immunol. 1996 PMID: 8902398
• Greene Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflun. Biochem.Pharmacol. 1995 PMID: 7575649

Product Documents for Leflunomide